Topamax, Qsymia, and Topiramate for Weight Loss: What the Trials Actually Show

Topiramate (Topamax) and the phentermine + topiramate ER combination Qsymia are the third major FDA-approved oral weight-loss option after the GLP-1 receptor agonists. The published evidence is strong: Bray 2003^[1] reported −6.3% body weight loss at 192-384 mg topiramate over 6 months in a dose-ranging RCT (n=385); Astrup 2004^[2] reported sustained −16.5% from baseline at 192 mg in a 44-week maintenance trial after an initial low-calorie diet run-in. The Qsymia Phase 3 program — EQUIP^[4], CONQUER^[5], and the SEQUEL 108-week extension^[6] — established Qsymia as producing roughly 10% sustained body weight loss at the 15 mg phentermine / 92 mg topiramate dose, plus a 78.7% reduction in incident type 2 diabetes. That magnitude is two-thirds of semaglutide and half of tirzepatide. The cognitive “dopamax” side effect, kidney stone risk (10.7% in long-term users), metabolic acidosis (40-71% abnormal bicarbonate), and the cleft palate teratogenicity (RR 5.16 at >100 mg topiramate) are real and shape who should use it. Generic phentermine/topiramate ER launched May 7, 2025, substantially lowering the cost barrier. Here is the verified evidence.

The original topiramate weight-loss trials (off-label)

Topiramate's weight-loss effect was discovered as a side effect during epilepsy and migraine trials and then formally studied for weight management before the Qsymia combination was developed.

Bray 2003^[1] randomized 385 obese adults to topiramate at 64, 96, 192, or 384 mg/day vs placebo over 6 months. Mean body weight changes:

• Placebo: −2.6%
• 64 mg: −5.0%
• 96 mg: −4.8%
• 192 mg: −6.3%
• 384 mg: −6.3%

Two important findings: the dose-response was real and statistically significant up to ~192 mg, and pushing past 192 mg added no additional weight benefit but caused more cognitive and CNS side effects. 192 mg/day ended up being the practical ceiling for monotherapy.

Astrup 2004^[2] studied topiramate as a long-term maintenance agent after an initial 8-week low-calorie diet that produced ~8% weight loss. 701 patients entered the run-in; 439 with adequate early loss were randomized to topiramate 96 mg, 192 mg, or placebo for 44 additional weeks. Total weight loss from baseline at 52 weeks:

• Placebo: −8.9% (regression toward baseline as the diet-only group regained)
• Topiramate 96 mg: −15.4%
• Topiramate 192 mg: −16.5%

The Astrup trial is the cleanest evidence that topiramate meaningfully prevents weight regain after a low-calorie diet, which is the hardest problem in weight management. The placebo arm regained as expected; the topiramate arms continued to lose weight through the maintenance phase.

Wilding 2004^[3] (n=1,289) tested topiramate at 96, 192, and 256 mg over 60 weeks. Results confirmed dose-dependent weight loss (−7.0% at 96 mg to −9.7% at 256 mg), with diminishing returns and rising side effects at higher doses.

The Qsymia Phase 3 program

Qsymia combines phentermine (a sympathomimetic appetite suppressant approved for weight loss in 1959) with topiramate ER (a CNS-acting appetite reducer) in a single once-daily capsule. The combination was developed because the two drugs work through different mechanisms and have complementary side-effect profiles — phentermine's nervousness offset by topiramate's sedation, for example.

EQUIP (Allison 2012)^[4] tested Qsymia in severely obese adults (BMI ≥35 with no specific comorbidity requirement). 1,571 patients were randomized to placebo, low-dose Qsymia (3.75/23), or full-dose Qsymia (15/92) for 56 weeks. Mean weight loss:

• Placebo: −1.6%
• Qsymia 3.75/23: −5.1%
• Qsymia 15/92: −10.9%

CONQUER (Gadde 2011)^[5] tested Qsymia in 2,487 overweight or obese adults (BMI 27-45) with at least two obesity-related comorbidities (hypertension, dyslipidemia, T2D, prediabetes, abdominal obesity). 56-week mean weight loss:

• Placebo: −1.4 kg
• Qsymia 7.5/46: −8.1 kg
• Qsymia 15/92: −10.2 kg (−9.8%)

Response rates at the 15/92 dose: 70% achieved ≥5% weight loss and 48% achieved ≥10%. CONQUER also showed meaningful improvements in BP, lipids, fasting glucose, and glycemic control.

SEQUEL (Garvey 2012)^[6] was the 108-week extension of CONQUER — one of the longest sustained obesity-pharmacology trials ever conducted. 487 patients continued for an additional 52 weeks. Total weight loss at week 108:

• Placebo: −2.5%
• Qsymia 7.5/46: −10.9%
• Qsymia 15/92: −12.1%

SEQUEL also reported a 78.7% relative reduction in incident T2D in non-diabetic Qsymia 15/92 patients vs placebo — a remarkably large diabetes-prevention signal. The trial established that Qsymia's weight loss is sustained for at least 2 years and that the cardiometabolic benefits compound.

Magnitude vs the modern GLP-1s

Side by side at the highest tested doses:

• Qsymia 15/92 (CONQUER 56-week): −9.8% body weight
• Semaglutide 2.4 mg (STEP-1, 68-week): −14.9%^[8]
• Tirzepatide 15 mg (SURMOUNT-1, 72-week): −20.9%^[9]

Qsymia produces approximately two-thirds of semaglutide's effect and half of tirzepatide's. That's better than metformin (~1/5 to 1/7) and better than the SGLT2 inhibitors. For patients who can't tolerate or afford a GLP-1, Qsymia is the next-best evidence-based oral option, with the longest sustained-loss data of any non-GLP-1 weight drug.

Topiramate mechanism and side effects

Topiramate has multiple known mechanisms of action: GABA-A modulation, voltage-dependent sodium channel blockade, glutamate receptor antagonism, and carbonic anhydrase inhibition. Which of these drives the weight effect is not entirely clear; appetite suppression, altered taste perception (especially of carbonated beverages), and increased satiety all play roles.

The side effects that limit topiramate use are the same ones that limit it in epilepsy and migraine prophylaxis:

• Cognitive effects (“dopamax”). Word-finding difficulty, slowed processing speed, memory impairment, and difficulty with concentration. The incidence is dose-dependent: roughly 10-20% at the lower Qsymia doses, climbing to 40-50%+ at the high monotherapy doses (192-384 mg) used in epilepsy and the Bray trial. Effects are reversible on discontinuation.
• Paresthesias (tingling in fingers and toes): 35-51% incidence depending on dose. Usually tolerable; potassium supplementation sometimes helps.
• Metabolic acidosis. 40-71% of long-term users have abnormal serum bicarbonate; usually mild and asymptomatic, occasionally requires dose adjustment or monitoring.
• Kidney stones. Maalouf 2010^[7] reported 10.7% symptomatic kidney stones and 20% asymptomatic stones (detected by CT) in long-term topiramate users (median dose 300 mg, median duration 48 months). Mechanism: hypocitraturia and elevated urine pH from carbonic anhydrase inhibition.
• Cleft lip / cleft palate teratogenicity. The 2011 FDA Drug Safety Communication^[11] reported a 21.3-fold increased risk of oral clefts in topiramate-exposed pregnancies, with a clear dose-response (RR 1.64 at ≤100 mg/day; RR 5.16 at >100 mg/day). This is why Qsymia ships with a REMS (Risk Evaluation and Mitigation Strategy) program: women of childbearing age must use effective contraception, and pregnancy testing is required before initiation and monthly during treatment.
• Mood effects. Depression-related adverse events occurred in 4-7% of Qsymia patients in CONQUER vs 4% on placebo — small absolute increase but worth monitoring.

FDA approval, dosing, and the discontinuation rule

Qsymia was FDA-approved July 17, 2012^[10] for chronic weight management in adults with:

• BMI ≥30, OR
• BMI ≥27 with at least one weight-related comorbidity

Doses available:

• 3.75 mg phentermine / 23 mg topiramate ER (starter, 14 days)
• 7.5 mg / 46 mg (standard maintenance)
• 11.25 mg / 69 mg (escalation)
• 15 mg / 92 mg (maximum)

The FDA-mandated discontinuation rule is notable: if a patient has lost <3% of body weight at 12 weeks on the 7.5/46 dose, the prescriber should escalate to 15/92 OR discontinue. If the patient has lost <5% at 12 weeks on 15/92, discontinuation is required because continued treatment is unlikely to produce clinically meaningful loss. This is a more rigid stopping rule than most obesity drugs carry, and it's built into the label.

Cost and generic availability (2026)

Generic phentermine/topiramate ER was first FDA-approved in June 2024 (Actavis Labs, Teva, Dr. Reddy's) and launched commercially on May 7, 2025. As of April 2026:

• Brand Qsymia: ~$200/month or more without insurance
• Generic phentermine/topiramate ER: substantially cheaper, often $50-100/month with discount programs
• Insurance coverage: historically poor. Medicare excludes weight-loss drugs as a class, so Qsymia and the GLP-1s are equally not covered. Roughly half of Medicaid plans do not cover; commercial plans vary widely. The generic launch may improve coverage modestly but most patients will still pay out of pocket.

At ~$50-100/month generic vs $149/month for Foundayo through LillyDirect or $349-499/month for Wegovy NovoCare, Qsymia is now competitive on price with the cheapest oral GLP-1, while delivering roughly two-thirds the weight loss. For patients without GLP-1 access this is a meaningful change.

Combining Qsymia with a GLP-1

There is no published RCT data on combining Qsymia with a GLP-1, and the combination is not FDA-approved. Some obesity-medicine specialists do use the combination off-label, typically for GLP-1 plateau cases, with cardiovascular monitoring (phentermine raises heart rate and blood pressure; GLP-1s raise heart rate by 2-4 bpm). The mechanistic concerns are real:

• Additive appetite suppression. Phentermine and GLP-1 both reduce appetite via different mechanisms; the combination can produce excessive nausea, vomiting, or insufficient caloric intake.
• Cardiovascular load. Heart rate and blood pressure effects compound. Baseline ECG and ongoing CV monitoring are warranted.
• Topiramate teratogenicity. The same REMS requirements apply; the combination does not relax them.

See our existing phentermine + GLP-1 article for the closer analog. The pure phentermine + GLP-1 combination has more clinical-experience documentation than the Qsymia + GLP-1 combination.

Topiramate's other FDA-approved indications

Topiramate is FDA-approved for:

• Epilepsy (partial seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome)
• Migraine prophylaxis (target dose ~100 mg/day)
• Chronic weight management in the Qsymia combination only (NOT as monotherapy)

Topiramate is also commonly used off-label for binge-eating disorder, bulimia, alcohol use disorder, and bipolar disorder. Patients on topiramate for one of these indications who happen to lose weight are experiencing a documented side effect — not the primary therapeutic effect.

Bottom line

• Topiramate monotherapy produces ~6-10% body weight loss at 96-256 mg over 6-12 months (Bray 2003, Wilding 2004).
• As a maintenance agent after diet-induced weight loss, topiramate prevents regain effectively (Astrup 2004: −16.5% from baseline at 192 mg over 52 weeks).
• Qsymia (phentermine + topiramate ER) at the 15/92 dose produces ~10% sustained weight loss out to 108 weeks (CONQUER, SEQUEL) and reduces incident T2D by 78.7%.
• Magnitude is roughly two-thirds of semaglutide and half of tirzepatide — better than metformin or SGLT2 inhibitors, less than GLP-1s.
• The cognitive (“dopamax”), kidney stone (10.7% long-term), metabolic acidosis (40-71%), and cleft palate teratogenicity (RR 5.16 at >100 mg) side effects are real and shape who should use it.
• Generic phentermine/topiramate ER launched May 7, 2025; cost is now competitive with the cheapest oral GLP-1.
• Combining Qsymia with a GLP-1 is off-label, not RCT-tested, and warrants cardiovascular monitoring and specialist oversight.

Related research and tools

• Can you take phentermine with a GLP-1? — the closest precedent for combining Qsymia with a GLP-1
• Metformin and non-GLP-1 diabetes drugs for weight loss — the other major non-GLP-1 oral option
• SGLT2 inhibitors vs GLP-1s — another comparator class
• Antidepressants and weight on a GLP-1 — bupropion / Contrave context
• GLP-1 pricing index — the cost half of the comparison
• GLP-1 BMI calculator — FDA eligibility for GLP-1s and comparison to Qsymia's BMI thresholds

Important disclaimer. This article is educational and does not constitute medical advice. Qsymia is contraindicated in pregnancy, hyperthyroidism, glaucoma, and during or within 14 days of MAOI use, and requires baseline pregnancy testing in women of childbearing age. Topiramate dose escalation should be slow to manage cognitive and metabolic side effects. Patients with a history of kidney stones, metabolic acidosis, or psychiatric disease should discuss alternative options with their prescriber. Every primary source cited here was independently verified against PubMed and FDA on 2026-04-08.